key: cord-0980047-a8u5y0j7
authors: Shah, Rashmi R.
title: Chloroquine and hydroxychloroquine for COVID‐19: Perspectives on their failure in repurposing
date: 2020-09-27
journal: J Clin Pharm Ther
DOI: 10.1111/jcpt.13267
sha: b7f81b0057c2ac646c68718d5c24048a62f110e4
doc_id: 980047
cord_uid: a8u5y0j7

WHAT IS KNOWN AND OBJECTIVE: Non‐clinical studies suggest that chloroquine (CQ) and hydroxychloroquine (HCQ) have antiviral activities. Early clinical reports of successful HCQ‐associated reduction in viral load from small studies in COVID‐19 patients spurred a large number of national and international clinical trials to test their therapeutic potential. The objective of this review is to summarize the current evidence on the safety and efficacy of these two agents and to provide a perspective on why their repurposing has hitherto failed. METHODS: Published studies and rapidly emerging data were reviewed to gather evidence on safety and efficacy of CQ and HCQ in patients with COVID‐19 infection or as prophylaxis. The focus is on clinically relevant efficacy endpoints and their adverse effects on QT interval. RESULTS AND DISCUSSION: At the doses used, the two agents, given alone or with azithromycin (AZM), are not effective in COVID‐19 infection. The choice of (typically subtherapeutic) dosing regimens, influenced partly by "QT‐phobia," varied widely and seems anecdotal without any pharmacologically reliable supporting clinical evidence. A substantial proportion of patients receiving CQ/HCQ/AZM regimen developed QTc interval prolongation, many with absolute QTc interval exceeding the potential proarrhythmic threshold, but very few developed proarrhythmia. WHAT IS NEW AND CONCLUSION: The strategy to repurpose CQ/HCQ to combat COVID‐19 infection is overshadowed by concerns about their QT liability, resulting in choice of potentially subtherapeutic doses. Although the risk of QT‐related proarrhythmia is real, it is low and manageable by careful monitoring. Recent discontinuation of HCQ from at least four large studies effectively marks the end of efforts at repurposing of CQ or HCQ for COVID‐19 infection. This episode leaves behind important questions on dose selection and risk/benefit balance in repurposing drugs generally.

originally investigated. 1 The term 'repurposing' has not been clearly defined but generally means the development of an out-of-patent drug for a novel pharmaco-therapeutic indication. 1 scientific studies has appeared at such an extraordinary rate that it is difficult to keep pace with them. 9 This review is a critical commentary on repurposing CQ and HCQ in combating COVID-19 infection, with particular focus on dose selection and perceived cardiotoxicity.

Chloroquine and HCQ are approved for both treatment and prophylaxis against malaria. Both have wide-ranging activities against bacteria, fungi, protozoa, parasites and viruses. 10, 11 Clinically, CQ is also approved for the treatment of hepatic amoebiasis.

In non-clinical studies, CQ and HCQ have shown a variety of pharmacological effects, leading to their use in other conditions. 12 For example, based on different mechanisms of action, both are approved for use in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and light-sensitive skin eruptions. Therefore, it could be argued that CQ and HCQ have already been repurposed for use in novel pharmaco-therapeutic indications unrelated to infections. Furthermore, CQ is reported to have antitumour activity 13 and in November 2014, preliminary findings led the European Commission to grant CQ an orphan drug designation for the treatment of glioma. 14 Chloroquine and HCQ have attracted much attention for their antiviral activity. CQ was first investigated as an antiviral agent in 1963. 15 The exact mechanism(s) of their antiviral activity is not clear but evidence suggests that 4-aminoquinolines such as CQ and HCQ have at least four mechanisms by which they may act against diverse RNA viruses and reduce the cytokine storms they generate.

These are (a) inhibition of viral entry; (b) inhibition of viral release into the host cell; (c) reduction of viral infectivity; and (d) immunomodulation. 13, 16 They inhibit viral release into the host cell by increasing late endosomal and lysosomal pH, resulting in impaired release of the virus from the endosome or lysosome. Since the release of the virus requires a low pH, the virus is unable to release its genetic material into the cell and replicate. CQ also seems to act as a zinc ionophore that allows extracellular zinc to enter the cell and inhibit viral RNA-dependent RNA polymerase. CQ inhibits thiamine uptake 17 but the significance of this effect in terms of its antiviral activity is unclear at present. 

Chloroquine was shown in vitro to have antiviral activity against severe acute respiratory syndrome (SARS) associated with coronavirus infection. 20 Since the appearance of the current pandemic with COVID-19, a virus closely related to SARS, there has been an unparalleled resurgence of interest in the potential value of CQ and HCQ against this infection which is associated with high morbidity and mortality. 21 This interest intensified following an endorsement of HCQ as a safe and effective prophylactic medication by US President Donald Trump despite little reliable evidence of its efficacy or safety. This endorsement was associated with an abrupt increase in the number of prescriptions for HCQ. 22, 23 A survey of 1197 professionals by the Heart Rhythm Society revealed substantial use of HCQ, with or without azithromycin (AZM), among the respondents in the treatment of COVID-19 patients. 24 

The pharmacokinetics of CQ and HCQ are complex but comparable. 12 In the indications approved, their efficacy is also comparable but in animal studies, HCQ has been reported to be significantly less toxic than CQ. 25 In humans, HCQ has also been reported to have lower retinal toxicity than CQ. 26 Therefore, HCQ has been studied more widely than CQ, both alone and in combination with AZM, as a potential therapy against COVID-19 infection. AZM is a macrolide antibiotic reported to be immunomodulatory and antiviral. It is also reported to reduce production of pro-inflammatory cytokines such as interleukin (IL)-8, IL-6 and tumour necrosis factor (TNF)-alpha, reduce oxidative stress and modulate T-helper functions. 27 Among the earliest studies claiming benefits of HCQ in patients with COVID-19 were two, one each from France and China, 28 • RECOVERY trial, 35 investigating survival, discharge, need for ventilation and need for renal replacement therapy, co-ordinated at the University of Oxford (UK) and

• ORCHID trial, 36 investigating clinical endpoints focussing on death and hospitalization, sponsored by the National Heart, Lung, and Blood Institute (US).

The principal findings of the main representative studies, reported as of 10 July, 2020, are summarized in Table 1 . A critical review of the earlier of these studies can be found elsewhere. 47 These studies, including to date the largest RECOVERY trial, show that at the doses used, CQ or HCQ (with or without AZM) is not effective in reduction of viral load, post-exposure prophylaxis, improving survival or reducing the need for respiratory support in hospitalized patients. However, these studies varied widely in terms of design, patient populations studied, intended indications (prophylactic or curative), sample size and the severity of infection. Although the US FDA had recommended 800 mg on day 1, followed by 400 mg daily for 4-7 days for the EUA, the dosing schedules of HCQ in these studies also varied widely as shown in Table 2 in terms of loading dose (range 400-2400 mg), maintenance dose (range 400-800 mg) and duration of maintenance treatment (range 1-14 days). Four studies also reported concomitant treatment with AZM (typically 500 mg on day 1 followed by 250 mg daily for 4 days).

Critically, based on anecdotal reports of efficacy in COVID-19

infection, HCQ began to be hoarded, thereby increasing its worldwide demand and creating a shortage for its approved use in RA and SLE with potentially serious consequences for these patients. 48, 49 In anticipation of product shortages, the FDA also issued product-specific guidance for CQ phosphate and for HCQ sulphate for generic drug manufacturers.

Although the study was retracted within 2 weeks of its (initial online) publication on 22 May 2020, it is relevant to consider here the multinational registry analysis by Mehra et al 50 because, like its earlier French counterpart, 29 it further demonstrates the adverse impact of premature application of inadequately validated data. This study of CQ and HCQ, with and without a macrolide, in 96 032 patients hospitalized with COVID-19, reported that each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias. Consequently, almost immediately, the use of HCQ in the DISCOVERY and the SOLIDARITY trials was temporarily suspended. Other European governments also followed suit, dealing further blows to the hopes promoted by the US President.

However, on 4 June 2020, Mehra et al 51 retracted their study following several concerns regarding the veracity of the data and analyses. Consequently, the WHO resumed the HCQ arm of the SOLIDARITY trial. On 5 June 2020, however, the RECOVERY investigators concluded following an interim analysis that HCQ had no beneficial effect and discontinued with immediate effect enrolment of patients to the HCQ arm of the trial. 52 During mid-June 2020, the FDA also determined that CQ and HCQ are unlikely to be effective in treating COVID-19 and revoked the EUA 53 and the HCQ arm was once again discontinued not only from the SOLIDARITY trial but also from the ORCHID trial.

Both CQ and HCQ have serious adverse effects, 54-56 particularly on cardiac repolarization that results in prolongation of the QT interval of the surface electrocardiogram (ECG). Drug-induced prolongation of QT interval is commonly due to inhibition of IKr, the principal outward current responsible for cardiac repolarization. When excessive (typically ≥ 500 ms) or in presence of other risk factors such as bradycardia or hypokalaemia, prolonged QT interval is often a precursor of potentially fatal ventricular tachyarrhythmia known as the torsade de pointes (TdP). TdP is usually self-terminating but in rare cases can degenerate into ventricular fibrillation.

Hydroxychloroquine, and to a lesser extent AZM, blocks the IKr current and their combination has a greater effect. 57 In addition, AZM also increases peak and late sodium current, thereby further delaying cardiac repolarization. 58 Clinically, CQ , HCQ and AZM have long been known to prolong QT interval and induce ventricular tachyarrhythmias including TdP. 59-62 AZM dose-dependently increases CQ-induced QTc interval prolongation. 61, 63 Early observations suggestive of efficacy of HCQ had already led to widespread off-label use of CQ and HCQ, with or without AZM, in routine clinical medicine to treat COVID-19 patients. [22] [23] [24] Consequently, there was a rapid increase in the number of reports of sudden or aborted deaths. Reports such as this and others led regulatory authorities to issue warnings concerning the proarrhythmic potential of these drugs when used without appropriate monitoring and outside hospital setting or clinical trials. 65, 66 In the efficacy studies summarized above, ECG monitoring was undertaken in 7 studies. When monitored, QTc interval Collectively, these five studies suggest that although a significant proportion of patients develop marked prolongation of QTc interval at the doses studied, the risk of a proarrhythmia is very small. Administration of tocilizumab, an IL-6 inhibitor, results in marked reduction in QT interval duration in these patients. 80 In another study, 80% of the 40 patients with TdP showed elevated CRP levels with an identifiable inflammatory disease in 18 (45%) of these cases. In these subjects, IL-6 (but not TNF-alpha and IL-1) level was ~15-20 times higher than in controls. In the inflammatory cohort,

where QTc prolongation was common, CRP reduction was associated with a decrease in IL-6 level and significant QTc shortening Overall evaluation of the available evidence (Table 1) shows that at the doses used, CQ or HCQ (with or without AZM) is not effective in reduction of viral load, post-exposure prophylaxis, improving survival or reducing the need for respiratory support in hospitalized patients. However, these studies were undertaken in absence of reliable information on the effective therapeutic dose or concentration of HCQ in COVID-19 patients. As shown in Table 2 , the dosing schedules of HCQ have varied widely. It is also likely that the effective doses and the level of efficacy are different in subgroups of patients with different viral loads and/or severity of disease.

If HCQ was effective against COVID-19 at the doses used, it would be expected that patients with SLE receiving long-term HCQ therapy (typically 200-400 mg daily for years) will be relatively protected from COVID-19 infection (pre-exposure prophylaxis).

Although it is almost impossible to compute this risk prospectively, available evidence shows that HCQ therapy at these doses does not confer protection to these patients. 90 The studies summarized in Table 3 show that at the doses used in QT-liability studies, typically HCQ 800 mg on day 1 followed by 400 mg daily for 4 days, 70 Table 3 and moderate-to-severe COVID-19 disease). HCQ was the most common therapeutic agent studied in 24 of these 31 trials, with potential total sample size of over 25 000 participants. In the wake of the results from the RECOVERY trial, the current status on the use of HCQ in these and other ongoing trials is unknown.

It is questionable whether the ongoing clinical trials will shed any further helpful light on the safety, efficacy and risk/benefit of CQ and HCQ in combating COVID-19 infection. At the doses used, the findings from the therapeutic RECOVERY trial 35 

Repurposing old drugs in oncology: opportunities with clinical and regulatory challenges ahead

Drug repositioning and repurposing: terminology and definitions in literature

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

Reversal of chemoresistance and enhancement of apoptosis by statins through downegulation of the NF-κB pathway

Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice

Statins and cancer: a systematic review and meta-analysis

Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals

phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)

Clinical trials for the prevention and treatment of COVID-19: current state of play

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

A review on possible modes of actions of chloroquine/hydroxychloroquine: repurposing against SAR-COV-2

Orphan Designation: Chloroquine for the Treatment of Glioma

Treatment of viral hepatitis with chloroquine

Coalition: advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy

Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review

Of chloroquine and COVID-19

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019

Association between US Administration endorsement of hydroxychloroquine for COVID-19 and outpatient prescribing

Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States

COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies

Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate

Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity

Macrolides and viral infections: focus on azithromycin in COVID-19 pathology

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Hydroxychloroquine and Azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Official statement from International Society of Antimicrobial Chemotherapy (ISAC)

FDA grants Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Silver Spring, MD: Food and Drug Administration

SOLIDARITY: An international randomised controlled trial to evaluate non-licensed COVID-19 treatments in addition to standard care among hospitalised patients

PRINCIPLE: Platform Randomised trial of INterventions against COVID-19 In older people. EudraCT Number

RECOVERY Trial (Randomised Evaluation of COVID-19 Therapy)

ORCHID: Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease

Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in longterm care hospitals?

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

A pilot study of Hydroxychloroquine in treatment of patients with common coronavirus disease-19

Zhejiang Da Xue Xue Bao Yi Xue Ban

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: observational comparative study using routine care data

Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial

Observational study of hydroxychloroquine in hospitalized patients with Covid-19

A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19

Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial

Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis

Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey

Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

RETRACTION-hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

RECOVERY trial: statement from the chief investigator

FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Silver Spring, MD: Food and Drug Administration

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

Assessment of hydroxychloroquine and chloroquine safety profiles-a systematic review and meta-analysis

Adverse drug reactions of hydroxychloroquine: analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data

Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19

Azithromycin causes a novel proarrhythmic syndrome

FDA drug label for ARALEN (chloroquine phosphate). ht tps://w w w.acces sdata.fda.gov/drugs at fda_docs/label/ 2018/00600 2s045 lbl

FDA drug label for PLAQUENIL (hydroxychloroquine sulphate)

FDA drug label for ZITHROMAX (azithromycin

Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports

QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm

Off-label'' use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

COVID-19: Reminder of Risk of Serious Side Effects with Chloroquine and Hydroxychloroquine

FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems

Enhanced ECG monitoring of COVID-19 patients. Heart Rhythm

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial

Chloroquine-induced QTc prolongation in COVID-19 patients

The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythmia Electrophysiol

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm

Assessment of QT intervals in a case series of patients with Coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit

Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus disease 2019 (COVID-19)

Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin

IL-6: relevance for immunopathology of SARS-CoV-2

Interleukin-6 in COVID-19: a systematic review and meta-analysis. medRxiv

Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response

Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation

Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis

Heart rate-corrected QT interval duration in rheumatoid arthritis and its reduction with treatment with the interleukin 6 inhibitor tocilizumab

Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes

Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients

Practice considerations on the use of investigational anti-COVID-19 medications: dosage, administration and monitoring

Endpoints used in phase III randomized controlled trials of treatment options for COVID-19

Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020

Hydroxychloroquine as prophylaxis for Coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials

An evidence mapping and analysis of registered COVID-19 clinical trials in China

Systematic review of the registered clinical trials of Coronavirus diseases 2019 (COVID-19)

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis

COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing

Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness

QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin

Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm

Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19

An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: possible benefits of intravenous lidocaine

Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society

Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol

Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic

QT interval prolongation under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection

The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine